The anticancer effect of MetAP2 inhibitors is thought to be a combination of MetAP2 inhibition in endothelial cells (i.e., antiangiogenic) and tumor cells (i.e., antiproliferative; ref. 6). This evidence concerns the gene METAP2 and neoplasm.